No, not confused, mate. It’s not particularly modern CEO-esque of her to use that language.
She intimates that she knows something about the trial data.
That ‘something’ is definitely, unequivocally market sensitive, whether it be good or bad.
She must release what she knows.
She isn’t listed as an Investigator, so, by definition, the trial data has been leaked to her.
The market has acted upon this, and we’ve seen the run up from $0.012....(not complaining)
As an aside, the several listed investigators, with ongoing access to this ‘beautiful’ data, have an unfair advantage, do they not?
Or you’re more an end-justifies-the-means kinda guy?
Add to My Watchlist
What is My Watchlist?
